Genetic Variations in Radiation and Chemotherapy Drug Action Pathways and Survival in Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy
Huai Liu,Bin Qi,Xiang Guo,Lin-Quan Tang,Qiu-Yan Chen,Lu Zhang,Ling Guo,Dong-Hua Luo,Pei-Yu Huang,Hao-Yuan Mo,Yan-Qun Xiang,Fang Qiu,Rui Sun,Ying Zhang,Ming-Yuan Chen,Yi-Jun Hua,Xing Lv,Lin Wang,Chong Zhao,Ka-Jia Cao,Chao-Nan Qian,Ming-Huang Hong,Hai-Qiang Mai
DOI: https://doi.org/10.1371/journal.pone.0082750
IF: 3.7
2013-01-01
PLoS ONE
Abstract:Background and Purpose: Treatment outcomes vary greatly in patients with nasopharyngeal carcinoma (NPC). The purpose of this study is to evaluate the influence of radiation and chemotherapy drug action pathway gene polymorphisms on the survival of patients with locoregionally advanced NPC treated with cisplatin-and fluorouracil-based chemoradiotherapy.Material and Methods: Four hundred twenty-one consecutive patients with locoregionally advanced NPC were prospectively recruited. We utilized a pathway approach and examined 18 polymorphisms in 13 major genes. Polymorphisms were detected using the LDR-PCR technique. Multifactor dimensionality reduction (MDR) analysis was performed to detect potential gene-gene interaction.Results: After adjustment for clinicopathological characteristics, overall survival was significantly decreased in patients with the MPO rs2243828 CT/CC genotype (HR=2.453, 95% CI, 1.687-3.566, P<0.001). The ERCC1 rs3212986 CC (HR=1.711, 95% CI, 1.135-2.579, P=0.010), MDM2 rs2279744 GT/GG (HR=1.743, 95% CI, 1.086-2.798, P=0.021), MPO rs2243828 CT/CC (HR=3.184, 95% CI, 2.261-4.483, P<0.001) and ABCB1 rs2032582 AT/AA (HR=1.997, 95% CI, 1.086-3.670, P=0.026) genotypes were associated with poor progression-free survival. Prognostic score models based on independent prognostic factors successfully classified patients into low-, intermediate-, and high-risk groups. Furthermore, MDR analysis showed no significant interaction between polymorphisms.Conclusions: Four single nucleotide polymorphisms were associated with survival in patients with locoregionally advanced NPC treated with cisplatin- and fluorouracil-based chemoradiotherapy. Combining clinical prognostic factors with genetic information was valuable in identifying patients with different risk.